EV71 vaccines: a milestone in the history of global vaccine development

Figures & data

Table 1 Summary of key features of three EV71 vaccines^1,2,3

Vaccine producer	Beijing Vigoo Biological	Sinovac Biotech	Institute of Medical Biology, CAMS^a
Total trial population	10245	10007	12000
Age (month)	6–35	6–35	6–71
Dosing	320 U	400 U	100 U
Immunization schedule (day)	0, 28	0, 28	0, 28
Adjuvant	Alum 0.18 mg	Alum - ^b	Alum 0.5 mg
Viral strain	FY7VP5/AH/CHN/2008 (genotype C4)	EV71 strain H07 (genotype C4)	An EV71 strain of genotype C4 isolated from Fuyan, China
Vaccine efficacy (against EV71-associated HFMD)	90.0%	94.8%	97.3%–97.4%

a Chinese Academy of Medical Sciences, CAMS.

b Alum dosing information is not included in Reference 2.

Li R, Liu L, Mo Z et al.An inactivated enterovirus 71 vaccine in healthy children. N Engl J Med2014;370: 829–837.

 PubMed Web of Science ®Google Scholar

Zhu F, Xu W, Xia J et al.Efficacy, safety, and immunogenicity of an enterovirus 71 vaccine in China. N Engl J Med2014;370: 818–828.

 PubMed Web of Science ®Google Scholar

Zhu FC, Meng FY, Li JX et al.Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet2013;381: 2024–2032.

 PubMed Web of Science ®Google Scholar